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This prospective, blinded observational study was conducted
to measure the predictive value the of flow cytometric
crossmatch for biopsy-proven acute rejection, graft loss, or
death following kidney transplantation. Patients were selected
for renal transplantation on the basis of a conventional
antihuman globulin cytotoxic T-cell crossmatch. Flow
crossmatch was performed simultaneously, but the results
were not disclosed to the transplant team. A total of 257
kidney transplant recipients were enrolled in the study; 78
patients experienced biopsy-proven rejection in the first post-
transplant year, and 41 patients lost their graft or died during
the period of follow-up (mean: 2046 days). Kaplan–Meier
estimates of rejection, graft loss, or patient death did not differ
between subjects with a positive or negative flow crossmatch.
Cox analyses showed no influence of the flow crossmatch on
the risk of biopsy-proven acute rejection (P¼ 0.987). The
sensitivity and specificity of the flow crossmatch for prediction
of biopsy-proven rejection were 0.128 and 0.883, and the
positive and negative post-test probabilities were 0.323 and
0.301, respectively. The magnitude of the channel shift did not
influence the multivariate Cox regression model. The area
under the receiver operating characteristic curve of the
flow crossmatch was 0.483 (P¼ 0.71) and 0.572 (P¼ 0.38),
respectively for the living and cadaver transplant recipients,
indicating no discriminative value in this study population.
Flow crossmatch appears to have no significant incremental
value in predicting biopsy-proven acute rejection, graft loss, or
death following kidney transplantation in patients who have
a negative antihuman globulin cytotoxic T-cell crossmatch
against their donor.
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Sensitive and specific biomarkers are critical in all areas of
medical practice to define risk, predict outcome, guide
therapy, and improve selection for clinical research.1–3 This is
particularly true in renal transplantation, where rapid
advances in immunological understanding and intervention
are driving important improvements in clinical outcomes.
The pre-transplant crossmatch is designed to detect
preformed immunoglobulin (IgG) antibodies against donor
human lymphocyte antigens (HLAs) in the recipient’s serum
which may cause antibody-mediated rejection and may
jeopardize graft survival.4–10 Anti-human globulin (AHG) is
currently routinely employed to enhance the sensitivity of the
conventional complement-dependent cytotoxic (CDC) cross-
match, and is the standard crossmatch method in the
majority of laboratories worldwide. The flow cytometry
crossmatch (FCXM) was first used for pre-transplant cross-
match in 1983.11 Although the assay offers no direct evidence
of biological effect or antigenic specificity, it is generally
accepted to be more sensitive than AHG-XM for detecting
low levels of anti-lymphocyte antibodies.10–15 On this basis,
the FCXM is now widely employed as a key pre-transplant
measure, and a positive FCXM has been proposed as a valid
rationale to withhold transplantation, to augment immuno-
suppression, or to employ innovative strategies to reduce
sensitization.16–18
A growing body of studies has examined the association
between FCXM and acute rejection in the last decade. As
reviewed in detail by Gebel and Bray,16 many of these reports
have suggested that FCXM-positive recipients experienced a
greater incidence of acute rejection and early graft loss,
especially among the subgroups of recipients at high
immunological risk,19–23 whereas other studies have shown
negative results or indicated little advantage of FCXM over
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the AHG-XM in terms of reducing acute rejection episodes
and graft loss.24–27 Few studies, however, have attempted to
define the predictive value of this assay in objective
terms,28,29 and none has undertaken this in a prospective
and blinded manner. The aim of this study was therefore to
measure the predictive value of donor T cell-directed IgG
FCXM for acute rejection and graft loss following kidney
transplantation under conditions of normal clinical practice.
The study was conducted in both living donor (LD) and
cadaveric donor (CD) recipients. FCXM was performed
before transplant but the result remained confidential and
was not employed for clinical decision purposes.
RESULTS
Patients
Patient characteristics are shown in Table 1. Of the 257
patients included in the study, 61% (156 patients) were male.
Their original diseases were glomerulonephritis (40.1%),
diabetic nephropathy (11.3%), cystic kidney disease (9.7%),
pyelonephritis or interstitial nephritis (9.3%), lupus nephritis
(6.2%), congenital disease (3.1%), and others (20.2%). One
hundred and ninety-seven patients (77%) received a first
graft and 60 (23%) a second or subsequent graft. Twenty
patients received induction therapy with depleting antibody,
and 27 (11%) experienced delayed graft function (DGF)
requiring dialysis. Compared with living donor transplants,
the cadaver donor recipients had a higher panel reactive
antibody (PRA) (median: 33 vs 0%), and a greater number of
second or subsequent grafts (56 vs 14%). A higher
proportion also received biological induction therapy with
OKT3 (32 vs 1%). The mean duration of follow-up for the
study was 2046 days (range: 0–3112 days).
FCXM results
Two hundred and twenty-six patients had a negative T-cell
FCXM. Among these, 173 patients had a 0 MCS; 37 had a
MCS between one and five MCS, and 16 were between six
and nine. A total of 31 (12.1%) patients had a positive T-cell
FCXM (range: 10–87 MCS). For two patients who experi-
enced primary graft non-function, the FCXM results were 0
and 18 MCS; for two with graft loss owing to venous
thrombosis, FCXM results were 0 and 2 MCS. Several key risk
factors were more common in patients with a positive FCXM
(Table 2), including PRA levels (median: 63 vs 0%), re-trans-
plantation (42 vs 21%), and cadaver donor (52 vs 18%).
Acute rejection
Of the 257 recipients who underwent transplantation
between January 1997 and December 2000, a total of 78
(30.4%) developed biopsy proven acute rejection (BPAR)
within the first year post-transplant (Table 3). Kaplan–Meier
estimates of the cumulative probabilities of BPAR are shown
in Figure 1. Of the 31 patients with a positive T-cell FCXM,
33.3% (Kaplan–Meier estimate) had BPAR within the first
year compared with 30.7% of the 226 subjects with a negative
FCXM (P¼ 0.907) (Figure 1a). The proportion of patients
with BPAR among the recipients of first or subsequent grafts
was 29.7 and 35.4% (P¼ 0.435) respectively. The incidence of
Table 1 | Demographic variables of study subjects according
to donor source
Living donor
(N=200)
Cadaver donor
(N=57)
FCXM (median shift) 0 (0,2) 0 (0,12)
PRA (%) 0 (0,3) 33 (0,73)
HLA-A,B mismatch number 2 (1,3) 2 (2,3)
HLA-DR mismatch number 1 (0,1) 1 (1,2)
Recipient age (years) 45 (34,54) 38 (32,52)
Donor age (years) 42 (35,49) 31 (16,51)
Regraft (%) 28 (14%) 32 (56%)
DGF (%) 18 (9%) 9 (16%)
Induction therapy (%) 2 (1%) 18 (32%)
Recipient serum CMV+ (%) 112 (56%) 41 (72%)
Donor serum CMV+ (%) 106 (53%) 24 (42%)
CMV, cytomegalovirus; DGF, delayed graft function; FCXM, flow cytometry cross-
match; HLA, human lymphocyte antigen; PRA, panel reactive antibody.
The values for FCXM, PRA, HLA-A, B mismatch number, HLA-DR mismatch number,
recipient age, and donor age were expressed as: median (first quartile, third
quartile).
Table 2 | Demographic characteristics of study subjects
according to flow crossmatch status
Negative FCXM
(N=226)
Positive FCXM
(N=31)
Panel reactive antibody (%) 0 (0,7) 63 (0,87)
HLA-A,B mismatch number 2 (1,3) 2 (2,3)
HLA-DR mismatch number 1 (0,1) 1 (1,1)
Recipient age (years) 43 (33,53) 37 (30,53)
Donor age (years) 42 (33,49) 37 (25,54)
Retransplant (%) 47 (21%) 13 (42%)
Cadaver donor (%) 41 (18%) 16 (52%)
Delayed graft function (%) 23 (10%) 4 (13%)
Recipient serum CMV+ (%) 134 (59%) 19 (61%)
Donor serum CMV+ (%) 117 (52%) 13 (42%)
CMV, cytomegalovirus; FCXM, flow cytometry crossmatch; HLA, human lymphocyte
antigen; PRA, panel reactive antibody.
The value for PRA, HLA-A, B mismatch number, HLA-DR mismatch number, recipient
age, and donor age were expressed as: median (first quartile, third quartile).
Table 3 | Contingency table showing frequency of BPAR and
graft failure or death (in brackets) according to patient group
and FCXM positivity
Patient category Event (+) Event () Total
Living donor
FCXM (+) 3 (1) 12 (14) 15
FCXM () 55 (24) 130 (161) 185
Cadaver donor
FCXM (+) 7 (5) 9 (11) 16
FCXM () 13 (11) 28 (30) 41
All patients
FCXM (+) 10 (6) 21 (25) 31
FCXM () 68 (35) 158 (191) 226
Total 78 (41) 179 (216) 257
BPAR, biopsy proven acute rejection; FCXM, flow cytometry crossmatch.
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BPAR was not significantly different between first graft
recipients with a positive (27.8%) or a negative (30.0%)
FCXM (P¼ 0.790), or between multiple graft recipients with
a positive (41.7%) or a negative FCXM (33.6%) (P¼ 0.754)
(Figure 1b). The proportion of patients with BPAR in the
living donor and cadaver donor transplant groups was 29.5
and 36.5%, respectively (P¼ 0.291). The incidence of BPAR
was not significantly different between live donor graft
recipients with a positive (20.0%) or a negative (30.2%)
FCXM (P¼ 0.386), or between cadaver graft recipients with
a positive (46.7%) or a negative (32.6%) FCXM (P¼ 0.501)
(Figure 1c). A total of 111 patients were treated for rejection
within the first year post-transplant. Comparable multi-
variate analyses showed no relationship between the prob-
ability of treated acute rejection and FCXM status in any of
the strata examined above.
Graft failure or death
A total of 41 patients (15.9%) lost their graft (n¼ 23, 8.9%)
or died (n¼ 18, 7.0%) during the period of follow-up
(Table 3). The proportions of patients surviving with a
functioning graft are shown in Figure 2. Of the 31 patients
with a positive T-cell FCXM, 6 (19.4%) lost their graft or
died compared with 35 of the 226 (17.8%) with a negative
FCXM, but there was no difference between the two groups
at 3000 days (Figure 2a) (P¼ 0.607). The proportion of
patients with graft failure or death among recipients of a first
or subsequent graft was 14.8 and 28.5%, respectively
(P¼ 0.003). There was no significant difference in either
group between patients with a positive or negative FCXM
(Figure 2b) (P¼ 0.872 for patients with first transplant and
P¼ 0.795 for patients with 41 transplants). The proportion
of patients with graft failure or death in the living donor and
cadaver donor transplant groups was 15.1 and 28.2%,
respectively (P¼ 0.004). The incidence of graft failure or
death was lower in living donor recipients with a positive
FCXM (6.7%) than in those with a negative FCXM (15.9%)
by 3000 days, but this difference was not statistically
significant (P¼ 0.444). This relationship was reversed in
cadaver graft recipients, where the proportion of patients
with graft failure or death in patients with a positive FCXM
(31.3%) was marginally but not significantly higher than in
those with a negative FCXM (26.9%) (P¼ 0.632). There was
no relationship between FCXM and either graft failure or
death when these outcomes were analyzed separately.
Cox regression
Two patients who did not have complete data on all
parameters were excluded from the Cox analysis. Patients
with graft failure were censored at the time of graft loss, and
those who died with functioning graft were censored at the
time of death. The multivariate Cox regression models
included T-cell FCXM, PRA level (PRA), HLA-A, B
mismatch number, HLA-DR mismatch number, number of
prior transplants, immunosuppression, plus donor and
recipient ages, and cytomegalovirus serum statuses. The only
demographic or treatment-related factor that was a signifi-
cant predictor for biopsy-proven acute rejection was HLA-A/
B mismatch (hazard ratios (HR) 1.292: P¼ 0.041). Trans-
plant number was a significant predictor of graft failure or
patient death (HR 2.119; P¼ 0.019), as was the patient
cytomegalovirus status (HR 0.459; P¼ 0.023). None of the
Cox regression models employed showed a significant
association between FCXM and either BPAR in the first year
(HR 0.993; P¼ 0.987), or graft failure or patient death during
the period of follow-up (HR 0.521; P¼ 0.246). Further
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Figure 1 | Kaplan–Meier estimate of time to first bBPAR by
(a) FCXM status, (b) FCXM status and graft number, and
(c) FCXM status and donor source.
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exploratory analyses included modeling the effect of FCXM
as a numeric predictor, as well as modeling donor source as a
covariate rather than as a stratification variable and including
the donor source by FCXM interaction in the Cox model
analysis. In all cases, results were very similar to those
described above.
Predictive value of FCXM
The predictive value of the T-cell FCXM was examined using
both dichotomous and continuous measures of assay
response. Employing a value of 10 MCS or more (Table 4),
the predetermined diagnostic standard for a positive FCXM,
the sensitivity and specificity were 0.128 and 0.883 for the
total study population, and the positive and negative
likelihood ratios (LRs) were close to 1 at 1.093 and 0.988,
respectively. The odds of BPAR were 0.436 (78/179); the
positive and negative post-test probabilities (PTPs) were
0.323 and 0.301, respectively. No improvement in the
predictive value was observed when patient groups were
analyzed separately. For living donor transplant recipients,
the sensitivity and specificity were 0.052 and 0.915,
respectively, and the positive and negative LRs were close
to 1 at 0.612 and 1.036, respectively. The prevalence of BPAR
was 0.290 (58/200) for the living donor transplant recipients,
and the positive and negative PTPs were therefore 0.200 and
0.297. For the group of patients with cadaver donors, the
sensitivity and specificity of the FCXM were 0.350 and 0.757,
and the positive and negative LRs were 1.439 and 0.859. The
prevalence of acute rejection in this subset of patients was
0.351 (20/57), so that the positive and negative PTPs were
0.438 and 0.317, respectively. Exploration of the quantitative
influence FCXM as a linear variable using ROC analysis
provided no additional contributory information. The
general performance of the FCXM was not significantly
different from chance alone, which can be expressed as the
diagonal straight line in each ROC plot (P¼NS). The area
under the curve for living transplant recipients was 0.483,
Table 4 | Clinical performance of FCXM in renal transplantation: sensitivity and specificity, LRs, and pre/post-test probabilities
Patient category Prevalenceee Sensitivity Specificity LR (+) LR () PTL (+) PTL ()
Living donor 0.290 0.052 0.915 0.612 1.036 0.200 0.297
Cadaver donor 0.351 0.350 0.757 1.439 0.859 0.438 0.317
All patients 0.304 0.128 0.883 1.093 0.988 0.323 0.301
LR, likelihood ratio; PTL, pre-test probabilities; PTP, post-test probabilities.
Su
rv
iva
l f
un
ct
io
n
Survival time (days)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Su
rv
iva
l f
un
ct
io
n
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Su
rv
iva
l f
un
ct
io
n
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0 1000 2000 3000 4000
Survival time (days)
0 1000 2000 3000 4000
Survival time (days)
0 1000 2000 3000 4000
Negative FCXM Positive FCXM
Positive FCXM and one tx Positive FCXM and > one tx
Negative FCXM and > one txNegative FCXM and one tx
Positive FCXM and CAD Positive FCXM and LD
Negative FCXM and LDNegative FCXM and CAD
a
b
c
Figure 2 | Kaplan–Meier estimate of time to graft loss or death
by (a) FCXM status, (b) by FCXM status and graft number, and
(c) by FCXM status and donor source.
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(P¼NS, Figure 3a), whereas for cadaver transplant recipients
it was 0.572 (P¼NS, Figure 3b).
DISCUSSION
FCXM has been employed as an adjunctive technique to
predict graft outcome in renal transplantation for over two
decades.11,15,16 During this time, evidence has accumulated to
indicate that this assay is more sensitive than conventional
CDC techniques, may detect antibodies which are undetected
by other routine crossmatch methods, and may provide
important predictive information regarding patient risk and
outcome.30 However, this information is complicated by
clinical, methodological, and analytical differences between
reports. Variable inter-laboratory consensus and false-nega-
tive rates point to concerns of assay precision and
specificity30,31 that may reflect differences in methodology
or equipment,30,32–34 in operator technique, or in criteria for
defining a positive result in different centers.33,35,36 In the
absence of clear evidence founded on prospective-blinded
studies, the objective prognostic performance of FCXM
remains unclear. There is consequently no universal policy
regarding its clinical application or agreement regarding its
predictive implications. Use of this technique, and the
therapeutic interpretation, remain at the discretion of the
transplant program or physician, and clinical response to a
positive test range from nil, to the use of intensified
immunosuppression, active desensitization, or withholding
of the transplant.
This study showed that when subjected to rigorous
analysis, T-cell FCXM did not provide incremental informa-
tion adequate to discriminate patients at high risk of acute
rejection, graft loss, or death. The patient cohort comprised
subjects across a broad range of anticipated risk throughout a
4-year period of care, who were then followed for up to 7
years post-transplant. Although patient selection and man-
agement remained reasonably constant during these periods,
several important risk factors were unequally distributed
between the FCXM- positive and-negative groups. Adjust-
ment for important confounders including donor age,
recipient PRA, HLA mismatch, immunosuppression, and
the occurrence of DGF after graft implantation37–40 was
therefore mandatory in order to determine the incremental
predictive value FCXM.
Five principal means are employed to control for
confounders: restriction, randomization, matching, stratifi-
cation, and multivariable analysis.41 Stratification and multi-
variable analysis were selected as the preferred options in this
study. Log-rank comparison of Kaplan–Meier estimates
showed no difference in the time to BPAR, or graft loss, or
death between patients with a positive or negative FCXM.
Cox models were stratified for living and cadaver transplant
recipients to account for differential risks associated with
donor source and immunological status. The models were
also fitted separately to the two patient subgroups in an
attempt to improve the precision with the achievement of
homoscedasticity, and all models were examined with and
without DGF as a covariate. These analyses showed no
independent predictive value of the FCXM in the current
patient sample.
Clinical performance of diagnostic tests is determined by
measures of discriminant capacity.42 Concordance with a
given disease state is determined by the true-positive
(sensitivity) and true-negative (specificity) rates, whereas
discordance is reflected by the false -positive and false-
negative rates. Incorporation of disease or event prevalence
enables the calculation of post-test probability, which
measures the predictive value of the test and indicates the
possibility of having the disease after the diagnostic result is
known. An ideal diagnostic test would therefore be both
sensitive and specific, with a high post-test probability when
the result was positive and a low post-test probability when
the result was negative.42
The sensitivity and specificity of the T-cell FCXM were
0.13 and 0.88, respectively, indicating that only 13% of
patients with biopsy-proven acute rejection had a positive
FCXM, whereas 88% of patients without biopsy-proven acute
rejection had a negative FCXM. In addition, the positive and
negative LRs were close to 1 in both the pooled data and
recipients subgroups showing that the capability of FCXM to
‘rule in’ or ‘rule out’ BPAR was very poor. ROC analysis was
employed to explore the predictive information obtained at
cutoff points higher or lower than the 10 MCS selected as the
diagnostic standard of the positive FCXM. This analysis
showed no significant relationship with BPAR, and implied
that FCXM provided no important gain in information for
clinical decision making at other cut-points.
The probability of BPAR in the study population (pre-test
probability) was 30.4%, consistent with the population
incidence of this event during this period of observation.
The presence of a positive FCXM increased this risk (post-
test probability) only marginally to 32.3%, whereas a negative
FCXM decreased the probability to 30.1%, providing little
discriminant clinical value. Because of the reported impor-
tance of FCXM for re-grafted and presensitized patients,19,20
the performance of FCXM was also assessed separately for
each subgroup of patients. FCXM offered no additional
predictive value in living DRs, and in fact a positive test was
associated with a decreased risk of BPAR. Among high-risk
cadaveric graft recipients in whom the pre-test probability of
BPAR was 35.1%, a positive FCXM increased the post-test
probability of BPAR to 43.8% whereas a negative test
decreased the post-test probability marginally to 31.7%.
Post-test probability is directly related to the population
prevalence of disease or event, and declines rapidly as this
prevalence decreases.3,42 We therefore applied the pooled test
results of this study to current practice, assuming a pre-test
rate of BPAR ranging from 5 to 15% as reported in recent
prospective studies.43–47 Positive (FCXM þ ) and negative
(FCXM ) PTPs of BPAR across this range would be 5.4 and
4.9%, respectively at the lower extreme, rising to 16.2
and 14.8% at the upper border. Even when the results of
the high-risk cadaver group are applied to the same pre-test
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range for BPAR, there is little evidence of important
discriminant value: positive and negative PTPs ranges from
7.0 to 4.3%, respectively at a pre-test BPAR of five, to 20.3
and 13.2% at a pre-test BPAR of 15%. This narrow range
provides little incremental value for clinical decision
formulation.
To ensure a high degree of risk distribution, the study
population was designed to include both low-risk living
donor and immunologically high-risk cadaver graft recipients
throughout the period of study. Low-risk primary cadaver
transplant recipients were therefore under-represented in the
analysis by comparison with the total transplant population,
and the ability of FCXM to predict acute rejection in such
patients is therefore less clear. For this reason, statistical
modeling was undertaken incorporating all 493 patients
transplanted during the 4 years of study, and allocating a
plausible range of outcomes between those exhibited by the
live donor and high-risk cadaver DRs. This analysis showed
no improvement in predictive value, even when all additional
patients were considered comparable to the high-risk cadaver
recipient group examined here (P¼ 0.480).
The T-cell FCXM assay was performed using a fluores-
cence-activated cell sorter with a 256 channel scale. The
threshold for a positive test was o10 MCS, comparable to a
value of 30–40 MCS using a 1024 channel scale. It is possible
that this cut-point is either too high or low, thereby
impacting the false-negative or false-positive rates. For this
reason we have analyzed the data in two additional ways.
First, in the Cox models stratified by donor source, we have
treated the FCXM result as a dichotomous variable (i.e. o10
MCS or p10 MCS) and as a continuous variable (i.e.
0-maximum value recorded). Second, we have employed a
receiver operating characteristic (ROC) curve analysis for the
combined and distinct (LD, DD) data to evaluate the point of
inflection, if such existed for any data set. As reported in the
text, neither of these approaches suggested either a clinically
or statistically significant influence of the FCXM assay at any
threshold.
In summary, this prospective, blinded study examined he
ability of T-cell FCXM to discern those recipients with high
risk of rejection, or graft loss or death. Based on its measured
performance, the FCXM was unable to provide clinically
important information to indicate a change in the selection
for transplantation. Kaplan–Meier analysis indicated that the
probability of acute rejection was not statistically different in
patients with a positive or negative FCXM, and ROC models
showed that the magnitude of FCXM had no effect on the
result obtained. Multivariate Cox analysis used to control for
confounders between study groups and to adjust for
important covariates showed no significant correlation
between test and clinical outcome. Finally, the PTPs did
not provide clinically important guidance in the selection of
patients according to subsequent risk. In concert, these
analyses suggest that FCXM not an independent predictor of
outcome and its application in predicting short-term or long-
term risk,48–50 or in determining patient selection or
immunosuppressive treatment may need to be re-evaluated.
It is likely that newer solid-phase assays, which demonstrate
comparable analytical sensitivity with greater analytical
specificity and hence exhibit a lower false-positive rate, may
supplant the FCXM in guiding patient selection or therapy,
but the clinical utility of these technologies remains to be
proven by rigorous prospective studies.
MATERIALS AND METHODS
Hypothesis
The study was conducted to test the hypothesis that T-cell FCXM
before transplantation in patients with a negative anti-donor AHG-
XM provides independent incremental prediction of graft rejection
or long-term outcome under conditions of normal clinical practice.
Patients
This prospective cohort study included 257 patients who underwent
renal transplantation between January 1997 and December 2000 at
the University of British Columbia, Vancouver, Canada. The study
included both living donor and cadaver graft recipients across a
spectrum of immunological risk. All donors and recipients were
ABO compatible, and all recipients had a negative donor T cell-
directed AHG-XM. FCXM was performed before transplantation,
but the results were not provided to the clinical team and did not
affect patient selection or treatment decisions. Patients were
followed in the University of British Columbia transplant program
up to the point of graft loss or death, and there was no loss to
follow-up during the period of observation.
Treatment
Before 1998 most patients received immunosuppression consisting
of cyclosporine, azathioprine, and prednisone. In 1998,
immunosuppression was changed to cyclosporine, prednisone,
and mycophenolate mofetil for the first transplant year, then
maintained as cyclosporine, azathioprine, and prednisone in the
following years. During this period of time 60 patients received
tacrolimus instead of cyclosporine; 12 patients received sirolimus;
and 20 patients at high immunological risk received induction
therapy with OKT3.
FCXM
T-cell FCXM was performed on fresh pre-transplant recipient serum
collected for conventional CDC. Donor lymphocytes were obtained
by gradient separation from the peripheral blood or donor spleen
and re-suspended in media. One million cell aliquots were
transferred into polystyrene tubes and pre-incubated with goat Ig
at 150 mg/tube (Caltag Laboratories Ltd, Burlington, CA, USA).
Negative control, positive control (pooled patient sera 490% PRA),
or patient’s sera (100 ml) were added to the cells and incubated at
41C for 30 min. Cells were washed twice before the addition of
3.75mg fluorescein isothiocyanate-conjugated anti-human IgG-Fc-
specific reagent to each tube (Jackson Research Laboratory Inc. West
Grove, PA, USA). They were incubated for 5 min followed by the
addition of 0.125 mg PerCP-conjugated anti-CD3 per tube (Beckton
Dickinson, San Jose, CA, USA). The tubes were further incubated at
41C for 30 min. The cells were then washed, fixed in 1% para
formaldehyde and analyzed by flow cytometry using a fluorescence-
activated cell sorter (Becton Dickinson) with a 256 channel log scale.
T-lymphocytes were gated according to their forward scatter and
side scatter properties and the positivity of the CD3 surface antigens.
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The crossmatch result was determined by the difference in the mean
fluorescence of the bound Fc-specific anti-IgG in the crossmatch
and the mean fluorescence of the bound Fc-specific anti-IgG in the
negative control, based on a double gating strategy, and a positive
T-cell FCXM was defined by a channel shift of p10 based on
statistical analysis of normal control distributions.51
Definition
Acute rejection episodes were diagnosed according to standard
clinical and laboratory criteria, and were confirmed by graft biopsy.
Acute rejection episodes were treated with intravenous pulse
methylprednisolone, and steroid-resistant episodes then received
either OKT3 or antilymphocyte globulin. Biopsy-proven or treated
acute rejection episodes were analyzed independently. DGF was
defined as a delay in the fall of serum creatinine with the need for
hemodialysis within the first week following transplantation.
Sensitivity meant the proportion of recipients with acute rejection
who were correctly identified by a positive FCXM. Specificity meant
the proportion of recipients without acute rejection who were
correctly identified by a negative FCXM.
Data analysis
Categorical variables were summarized using frequency and
percentages whereas continuous variables were summarized using
the median and first and third quartiles, [Q1, Q3], unless otherwise
indicated. Times to acute rejection during the first year post-
transplant, and graft loss, or death at any time were analyzed using
survival methods. Patients not experiencing these events were
censored at the latest point of follow-up. The log-rank test was used
to compare Kaplan–Meier estimates of BPAR in patients with a
positive (10 MCS or greater) and negative FCXM, with and without
stratification for transplant number and donor source. The
combined effects of multiple risk factors were explored using Cox
proportional hazard models stratified by donor type (cadaveric vs
living donor). Covariates in the models included the T-cell FCXM,
PRA level (PRA), HLA-A, B mismatch number, number of HLA-DR
mismatches, number of prior transplants, immunosuppression,
donor and recipient ages, and cytomegalovirus serum statuses. DGF
was treated as a contingent risk factor, being both a consequence of
sensitization and cause of graft rejection/loss, and analysis was
performed with and without DGF as a covariate. Exploratory
backwards elimination was also used to identify important
predictors; however, P-values and HRs were based on the full
multivariate regression model. ROC curves were drawn to show the
general performance of FCXM. Sensitivity and specificity were
calculated at the cut-point of 10 MCS of FCXM. Positive (PTPþ )
and negative PTPs (PTP) were calculated to measure the
predictive value of FCXM.3,28 The positive LR (þ ) and the negative
LR () provide clear measurements of the ‘ruling-in’ and ‘ruling
out’ capabilities of a test. A LR (þ ) exceeding 10 was considered
reasonable evidence that acute rejection would be highly likely
happen when the FCXM was positive; 2–5 was considered poor to
fair. A LR () less than 0.1 was considered reasonable evidence to
rule out acute rejection, whereas 0.2–0.5 was poor to fair. P was the
prevalence of acute rejection.
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